Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- ANCA-asociované vaskulitidy farmakoterapie imunologie MeSH
- buněčná imunita účinky léků MeSH
- dospělí MeSH
- humorální imunita účinky léků MeSH
- imunoglobulin G krev MeSH
- imunologické faktory farmakologie terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- myší monoklonální protilátky farmakologie terapeutické užití MeSH
- rituximab MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- imunoglobulin G MeSH
- imunologické faktory MeSH
- myší monoklonální protilátky MeSH
- rituximab MeSH
Rituximab (RTX) was reported effective in ANCA-associated vasculitis (AAV). We aimed to evaluate clinical efficacy of RTX in AAV along with its impact on immunological parameters. Eighteen RTX-treated AAV patients (M/F 11/7; median age 37.5; 15× PR3-ANCA, 3× MPO-ANCA; 16× relapsing/refractory, 2× first-line therapy) were enrolled. Clinical response, ANCA, total serum IgG levels and cellular immunity parameters were examined. The patients were followed up (FU) for a median of 26 months (range 3-82, 15 for ≥6 months). All patients achieved B cell depletion (lasting 3-24 months). No significant increase was noted in T cell or NK cell subpopulations. At 6 months, partial remission was achieved in 5/15 patients (33 %) and complete in 8 (53 %). The median prednisone dose (30..10 mg/d) and ANCA levels (17.2..2.7 IU/mL) decreased (p < 0.01). RTX retreatment was used in nine (8× pre-emptive, 1× relapse). Six patients relapsed (none of the pre-emptively treated). Three patients died of infection. IgG levels at 3 months decreased compared to baseline (9.0 vs 5.7 g/L, p < 0.01). Higher percentage of HLA-DR+CD3+ cells and lower percentage of CD4+CD45RA+ naive T cells persisted during FU. IFN-γ production increased at 6 months compared to baseline (27.3 vs 41.5 %). No significant change was noted in the intracellular IL-10 and IL-12 production. RTX helped to lower the glucocorticosteroids dose and withdraw cytotoxic drugs in most AAV patients. Hypogammaglobulinaemia was common but well tolerated. Peripheral circulating T cells remained activated despite B cell depletion.
Zobrazit více v PubMed
Clin Immunol. 2008 Jun;127(3):280-5 PubMed
Arthritis Rheum. 2012 Nov;64(11):3770-8 PubMed
Arthritis Rheum. 2005 Feb;52(2):501-13 PubMed
Arch Med Res. 2009 May;40(4):276-84 PubMed
Am J Respir Crit Care Med. 2006 Jan 15;173(2):180-7 PubMed
Arthritis Rheum. 2012 Nov;64(11):3760-9 PubMed
Arthritis Rheum. 2009 Jul;60(7):2156-68 PubMed
Arthritis Rheum. 2013 Jan;65(1):1-11 PubMed
Arthritis Rheum. 2009 Dec;60(12):3563-71 PubMed
PLoS One. 2012;7(5):e37626 PubMed
N Engl J Med. 2010 Jul 15;363(3):211-20 PubMed
Am J Nephrol. 2011;34(2):175-80 PubMed
Arthritis Rheum. 2011 Jun;63(6):1507-16 PubMed
N Engl J Med. 2010 Jul 15;363(3):221-32 PubMed
J Immunol. 2012 May 15;188(10):4747-58 PubMed
Nephrol Dial Transplant. 2006 Jul;21(7):1825-32 PubMed
Rheumatology (Oxford). 2006 Nov;45(11):1432-6 PubMed
Nephrol Dial Transplant. 2014 Jun;29(6):1151-9 PubMed
Ann Rheum Dis. 2007 Mar;66(3):283-92 PubMed
